Abstract

Constitutional loss-of-function pathogenic variants in the tumor suppressor genes BRCA1 and BRCA2 are widely associated with an elevated risk of ovarian cancer (OC). As only ~15% of OC individuals carry the BRCA1/2 pathogenic variants, the identification of other potential OC-susceptibility genes is of great clinical importance. Here, we established the prevalence and spectrum of the germline pathogenic variants in the BRCA1/2 and 23 other cancer-related genes in a large Polish population of 333 unselected OC cases. Approximately 21% of cases (71/333) carried the BRCA1/2 pathogenic or likely pathogenic variants, with c.5266dup (p.Gln1756Profs*74) and c.3700_3704del (p.Val1234Glnfs*8) being the most prevalent. Additionally, ~6% of women (20/333) were carriers of the pathogenic or likely pathogenic variants in other cancer-related genes, with NBN and CHEK2 reported as the most frequently mutated, accounting for 1.8% (6/333) and 1.2% (4/333) of cases, respectively. We also found ten pathogenic or likely pathogenic variants in other genes: 1/333 in APC, 1/333 in ATM, 2/333 in BLM, 1/333 in BRIP1, 1/333 in MRE11A, 2/333 in PALB2, 1/333 in RAD50, and 1/333 in RAD51C, accounting for 50% of all detected variants in moderate- and low-penetrant genes. Our findings confirmed the presence of the additional OC-associated genes in the Polish population that may improve the personalized risk assessment of these individuals.

Highlights

  • Ovarian carcinoma (OC), one of the most common gynecological malignancies, accounts for an estimated 239,000 new cases and 152,000 deaths worldwide annually, with the highest incidence rate in Central and Eastern Europe (11.4 per 100,000) [1]

  • All individuals included in this study had the comprehensive BRCA1/2 molecular screening as a part of our previous study [11]

  • Pathogenic variants were found in 71 cases (n = 71/333; 21.3%), with the vast majority of variants located in BRCA1 (n = 60/71; 84.5%), and only eleven in

Read more

Summary

Introduction

Ovarian carcinoma (OC), one of the most common gynecological malignancies, accounts for an estimated 239,000 new cases and 152,000 deaths worldwide annually, with the highest incidence rate in Central and Eastern Europe (11.4 per 100,000) [1]. The 5-year relative survival rate for all stages combined increased from 33.7% in 1975 to almost 50% in 2009 [2], OC is still the leading cause of death from cancer in women. The epithelial neoplasms are divided into five main subtypes (serous, endometrial, mucinous, clear cell and transitional cell tumors) that have different genetic risk factors, treatment responses, and prognosis. High-grade serous ovarian carcinoma represents approximately 70% of OC, followed by endometrial and clear cell cancer (10% each) [4]. The first-line treatment includes optimal cytoreductive surgery and platinum-based chemotherapy; chemotherapy sensitivity varies widely among individuals, depending mostly on the tumor’s histologic subtype with its grade, as well as the overall cancer stage [5,6]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call